Interactions between angiotensin AT1 receptor antagonists and second-generation antiepileptic drugs in the test of maximal electroshock

Fundamental and Clinical Pharmacology

Volumn 28, Issue 3, 2014, Pages 277-283

  Łukawski, Krzysztof ^a   Janowska, Agnieszka ^a   Jakubus, Tomasz ^a   Czuczwar, Stanisław J ^a,b  

^a INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Antiepileptic drugs; Drug interactions; Losartan; Maximal electroshock; Telmisartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT;

ANIMAL; ANIMAL BEHAVIOR; AVOIDANCE BEHAVIOR; BRAIN; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; ELECTRIC SHOCK; MALE; METABOLISM; MOTOR ACTIVITY; MOUSE; PATHOPHYSIOLOGY; SEIZURES;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTICONVULSANTS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROSHOCK; MALE; MICE; MOTOR ACTIVITY; SEIZURES;

EID: 84899119794     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12023     Document Type: Article

References (40)

1. Bunnemann B., Fuxe K., Ganten D. The renin-angiotensin system in the brain: an update 1993. Regul. Pept. (1993) 46 487-509.
2. Wright J.W., Harding J.W. Brain renin-angiotensin - a new look at an old system. Prog. Neurobiol. (2011) 95 49-67.
3. Steckelings U.M., Rompe F., Kaschina E., Unger T. The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundam. Clin. Pharmacol. (2009) 23 693-703.
4. Tchekalarova J., Georgiev V. Angiotensin peptides modulatory system: how is it implicated in the control of seizure susceptibility? Life Sci. (2005) 76 955-970.
5. Pereira M.G., Becari C., Oliveira J.A., Salgado M.C., Garcia-Cairasco N., Costa-Neto C.M. Inhibition of the renin-angiotensin system prevents seizures in a rat model of epilepsy. Clin. Sci. (Lond) (2010) 119 477-482.
6. 1 receptor antagonists enhance the anticonvulsant action of valproate in the mouse model of maximal electroshock. Eur. J. Pharmacol. (2010) 640 172-177.
7. Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure (2011) 20 359-368.
8. Farsang C. Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk. Vasc. Health Risk. Manag. (2011) 7 605-622.
9. Escobar C., Barrios V. Combined therapy in the treatment of hypertension. Fundam. Clin. Pharmacol. (2010) 24 3-8.
10. Ruiz-Giménez J., Sánchez-Alvarez J.C., Cañadillas-Hidalgo F., Serrano-Castro P.J., Andalusian Epilepsy Society. Antiepileptic treatment in patients with epilepsy and other comorbidities. Seizure (2010) 19 375-382.
11. Culman J., von Heyer C., Piepenburg B., Rascher W., Unger T. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats. Eur. J. Pharmacol. (1999) 367 255-265.
12. 1 receptor blockers. J. Cardiovasc. Pharmacol. (2003) 41 593-599.
13. 1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J. Pharmacol. Exp. Ther. (2001) 298 62-70.
14. Łuszczki J.J., Czuczwar S.J. Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia (2004) 45 895-907.
15. Raghavendra V., Chopra K., Kulkarni S.K. Involvement of cholinergic system in losartan-induced facilitation of spatial and short-term working memory. Neuropeptides (1998) 32 417-421.
16. Tracy H.A. Jr., Wayner M.J. Losartan blocks diazepam and ethanol effects on air righting. Alcohol (1998) 16 93-99.
17. Swinyard E.A., Brown W.C., Goodman L.S. Comparative assays of antiepileptic drugs in mice and rats. J. Pharmacol. Exp. Ther. (1952) 106 319-330.
18. Venault P., Chapouthier G., Prado de Carvalho L. et al. Benzodiazepine impairs and β-carboline enhances performance in learning and memory tasks. Nature (1986) 321 864-866.
19. Boissier J.R., Tardy J., Diverres J.C. Une nouvelle methode simple pour explorer l'action 'tranquilisante': le test de la cheminee. Med. Exp. (Basel) (1960) 3 81-84.
20. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. (1949) 96 99-113.
21. Łuszczki J.J., Borowicz K.K., Świader M., Czuczwar S.J. Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia (2003) 44 489-499.
22. Noh H.J., Kang Y.S., Lim D.Y. Effects of losartan on catecholamine release in the isolated rat adrenal gland. Korean J. Physiol. Pharmacol. (2009) 13 327-335.
23. Kim H.K., Youm J.B., Lee S.R. et al. The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action. Pflugers Arch. (2012) 464 631-643.
24. Kwan P., Sills G.J., Brodie M.J. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol. Ther. (2001) 90 21-34.
25. Ahmad S., Fowler L.J., Whitton P.S. Lamotrigine, carbamazepine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids. Epilepsy Res. (2005) 63 141-149.
26. Meldrum B.S., Akbar M.T., Chapman A.G. Glutamate receptors and transporters in genetic and acquired models of epilepsy. Epilepsy Res. (1999) 36 189-204.
27. Lee C.Y., Fu W.M., Chen C.C., Su M.J., Liou H.H. Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus. Epilepsia (2008) 49 888-897.
28. Samoriski G.M., Piekut D.T., Applegate C.D. Differential spatial patterns of Fos induction following generalized clonic and generalized tonic seizures. Exp. Neurol. (1997) 143 255-268.
29. 1 receptor. Peptides (1995) 16 1069-1071.
30. + current fractions by the new anticonvulsant topiramate. J. Pharmacol. Exp. Ther. (1999) 288 960-968.
31. 3H]glutamate in hippocampal nerve endings. Neuropharmacology (2007) 52 598-605.
32. Patsalos P.N., Fröscher W., Pisani F., van Rijn C.M. The importance of drug interactions in epilepsy therapy. Epilepsia (2002) 43 365-385.
33. Patsalos P.N., Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. (2003) 2 347-356.
34. Ebner T., Heinzel G., Prox A., Beschke K., Wachsmuth H. Disposition and chemical stability of telmisartan 1-O-acylglucuronide. Drug Metab. Dispos. (1999) 27 1143-1149.
35. Wienen W., Entzeroth M., van Meel J.C.A. et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc. Drug Rev. (2000) 18 127-154.
36. Yan F., Hu Y., Di B., He P.L., Sun G. Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. J. Pharm. Pharm. Sci. (2012) 15 208-220.
37. Shorvon S. Handbook of epilepsy treatment, 3rd edn, Wiley-Blackwell, Oxford, UK, 2010.
38. Spina E., de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin. Pharmacol. Toxicol. (2007) 100 4-22.
39. Hollenberg P.F. Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab. Rev. (2002) 34 17-35.
40. Taavitsainen P., Kiukaanniemi K., Pelkonen O. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur. J. Clin. Pharmacol. (2000) 56 135-140.